The plasma levels of Caspase-3 before and after perfusion in patient with STEMI at different ischemic times

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025223

Enrollment

Unknown

Registered

2019-08-17

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-segment elevation myocardial infarction

Interventions

Case series:Emergency PCI

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: The inpatients of STEMI between September 1st 2019 and November 30th 2019 will be included. AMI was diagnosed clinically on the basis of symptoms, electocardiographic changes, and increased serum levels of cardiac enzymes.

Exclusion criteria

Exclusion criteria: 1. Combined with sever pulmonary infection; 2. Combined with cardiogenic shock; 3. Combined with acute cerebral infarction; 4. Combined with sever trauma; 5. Performed CPR after after STEMI onset; 6. Combined with malignant tumor or leukemia; 7. In the acute phase of autoimmune disease; 8. Combined with myocarditis or post-infarction syndrome.

Design outcomes

Primary

Measure	Time frame
caspase-3;	—

Countries

China

Contacts

Public ContactYuanping Zhao

Cangzhou Central Hospital

18333090212@163.com+86 18333090212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026